ABSTRACT NUMBER: ESOC2026YS54 RISK FACTORS FOR THE DEVELOPMENT OF LABORATORY RESISTANCE TO ACETYLSALICYLIC ACID IN SECONDARY PREVENTION IN PATIENTS AFTER ATHEROTHROMBOTIC ISCHEMIC STROKE

Abstract Background and aims Effective antiplatelet therapy after ischemic atherothrombotic stroke (IAS) is one of the priorities in secondary prevention.The development of laboratory resistance (LR) against the background of acetylsalicylic acid (ASA) intake can lead to the development of a second cerebral stroke in this category of patients. Aim: to identify clinical and demographic predictors of LR in patients with IAS who are taking ASA. Methods A one-stage cross-sectional analytical study of clinical and genetic risk factors was conducted in 238 patients with IAS who were taking ASA. Statistical analysis was performed using SPSS 26. The relationship was evaluated using multivariate logistic modeling, Pearson's test, and Fisher's test. Differences were considered significant at p < 0.05. Results LR to ASA was detected in 16 women (40%) and 24 men (60%), the absence of LR to ASA - 138 men (69.7%) and 60 women (30.3%), the average age of 52.93 ±15.05 years and 59 ± 10.96 years, respectively. No AA mutation was detected in the CYP2C19*3 gene, and the results were statistically insignificant by gender (OR 1.53; 95% CI 0.76-3.09; p=0.23).Analysis of the prevalence of factors depending on the presence or absence of LR (Table1) and based on the values of regression coefficients, an increase in age by 1 year increases the chances of LR by 0.94 times (95% CI: 0.91-0.97. p<0.001), smoking by 0.34 times (95% CI: 0.15-0.75. p=0.007), taking BCC by 4.27 times (95% CI: 1.86-9.81. p=0.001), the presence of the CYP2C19 3 GG gene was 0.07 times (95% CI: 0.01-0.57. p=0.013) Conflict of interest Name of author: nothing to disclose Table 1 - belongs to Results